(ROCKVILLE, Md.)Biotechnology company Emergent BioSolutions Inc. said Wednesday it will receive between $364 million and $404 million for new contracts to supply the U.S. government with anthrax v...READ MORE

(ROCKVILLE, Md.)Biotech company Emergent Biosolutions said Wednesday it received a $24.3 million contract to continue development of its experimental anthrax treatment.READ MORE

(WASHINGTON)Biopharmaceutical company Emergent BioSolutions Inc. spent $560,000 lobbying the federal government in the second quarter, according to a recent disclosure form.READ MORE

Among the earnings stories for Thursday, Aug. 7, from AP Financial News: HOUSTON (AP)--Shares of Key Energy Services Inc. wavered Thursday after the oil drilling services company s...READ MORE

(ROCKVILLE, Md.)Emergent BioSolutions Inc. said Thursday it swung to a second-quarter profit on higher sales of its anthrax vaccine BioThrax. But, shares plunged as the company said it will likely...READ MORE

(MERIDEN, Conn.)Privately held Protein Sciences Corp. on Tuesday said it will not sell to fellow biotechnology company Emergent BioSolutions Inc., citing breaches of the buyout agreement, but Emer...READ MORE

(WASHINGTON)Biopharmaceutical company Emergent BioSolutions Inc. spent $550,000 lobbying in the first quarter, according to a recent disclosure form. Emergent BioSolutions lobbied on the gover...READ MORE